Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

First Posted Date: 2006-12-22

Last Posted Date: 2012-07-06

Lead Sponsor: AEterna Zentaris

Target Recruit Count: 32

Registration Number: NCT00415064

VELCADE,Rituximab,Cyclophosphamide and Decadron

Phase 2

Terminated

Conditions: Lymphoma, B-Cell
Lymphoma, Non-Hodgkin

Interventions: Drug: VELCADE®
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Decadron

First Posted Date: 2006-12-20

Last Posted Date: 2018-09-19

Lead Sponsor: Oncology Specialists, S.C.

Target Recruit Count: 12

Registration Number: NCT00413959

Locations: 🇺🇸
Onocology Specialists, S.C, Niles, Illinois, United States
🇺🇸
Oncology Specialists, S.C, Park Ridge, Illinois, United States

Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia

Phase 4

Completed

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2006-12-14

Last Posted Date: 2006-12-14

Lead Sponsor: International BFM Study Group

Target Recruit Count: 2600

Registration Number: NCT00411541

Locations: 🇦🇷
Department of Pediatric Hematology-Oncology, Italian Hospital, Buenos Aires, Argentina
🇧🇪
Department of Pediatric Hemato-Oncology, Gent University Hospital, Gent, Belgium
🇦🇹
Children's Cancer Research Institute, St Anna Kinderspital, Vienna, Austria

and more 5 locations

Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)

Not Applicable

Completed

Conditions: Nausea
Sarcoma
Vomiting

Interventions: Drug: Palonosetron - Single Dose
Drug: Palonosetron - Triple Dose
Drug: Adriamycin
Drug: Ifosfamide chemotherapy (AI)
Drug: Zinecard
Drug: Mesna
Drug: Vincristine
Drug: Dexamethasone

First Posted Date: 2006-12-13

Last Posted Date: 2013-03-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 51

Registration Number: NCT00410488

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma

Phase 2

Completed

Conditions: Stage II Multiple Myeloma
Multiple Myeloma in Relapse
Stage III Multiple Myeloma

Interventions: Biological: bevacizumab
Drug: lenalidomide
Drug: dexamethasone

First Posted Date: 2006-12-13

Last Posted Date: 2017-09-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT00410605

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

Phase 2

Completed

Conditions: Liver Cancer

Interventions: Biological: bevacizumab
Drug: dexamethasone
Drug: floxuridine
Genetic: protein expression analysis
Other: flow cytometry
Other: immunoenzyme technique
Other: immunohistochemistry staining method
Other: immunologic technique
Other: laboratory biomarker analysis
Procedure: dynamic contrast-enhanced magnetic resonance imaging

First Posted Date: 2006-12-13

Last Posted Date: 2024-12-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 22

Registration Number: NCT00410956

Locations: 🇺🇸
New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Phase 3

Active, not recruiting

Conditions: T Acute Lymphoblastic Leukemia
T Lymphoblastic Lymphoma

Interventions: Drug: Cytarabine
Drug: Cyclophosphamide
Drug: Asparaginase
Other: Laboratory Biomarker Analysis
Drug: Daunorubicin Hydrochloride
Drug: Methotrexate
Drug: Mercaptopurine
Drug: Leucovorin Calcium
Drug: Dexamethasone
Drug: Pegaspargase
Drug: Doxorubicin Hydrochloride
Drug: Prednisone
Drug: Nelarabine
Drug: Vincristine Sulfate
Radiation: Radiation Therapy
Drug: Thioguanine

First Posted Date: 2006-12-05

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1895

Registration Number: NCT00408005

Locations: 🇺🇸
Scott and White Memorial Hospital, Temple, Texas, United States
🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States

and more 212 locations

Dexamethasone for Paediatric Adeno-tonsillectomy - A Dose-finding Study

Phase 4

Terminated

Conditions: Postoperative Nausea and Vomiting
Postoperative Pain

Interventions: Drug: Saline
Drug: Dexamethasone

First Posted Date: 2006-11-27

Last Posted Date: 2010-08-16

Lead Sponsor: University Hospital, Geneva

Target Recruit Count: 215

Registration Number: NCT00403806

Locations: 🇨🇭
University Hospital of Geneva, Anesthesia Department, Geneva, Canton of Geneva, Switzerland

Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Metastatic Breast Cancer

Interventions: Drug: Lapatinib
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Docetaxel
Drug: Pegfilgrastim
Drug: Filgrastim
Drug: Dexamethasone
Drug: Trastuzumab

First Posted Date: 2006-11-27

Last Posted Date: 2017-12-22

Lead Sponsor: George Albert Fisher

Target Recruit Count: 21

Registration Number: NCT00404066

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸
Santa Clara Valley Medical Center, San Jose, California, United States

Dexamethasone and Supportive Care With or Without Whole-Brain Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer That Has Spread to the Brain and Cannot Be Removed By Surgery

Phase 3

Completed

Conditions: Lung Cancer
Metastatic Cancer

First Posted Date: 2006-11-23

Last Posted Date: 2013-08-26

Lead Sponsor: Medical Research Council

Target Recruit Count: 1000

Registration Number: NCT00403065

Locations: 🇬🇧
Wansbeck General Hospital, Ashington, England, United Kingdom
🇬🇧
Sussex Cancer Centre at Royal Sussex County Hospital, Brighton, England, United Kingdom
🇬🇧
Whiston Hospital, Prescot Merseyside, England, United Kingdom

and more 66 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy